For the quarter ending 2025-12-31.
| Income Statement | 2025-12-31 | 2025-09-30 | 2025-06-30 | |
|---|---|---|---|---|
| Research and development | 1,124,727 | 851,537* | 939,067 | |
| General and administrative | 1,216,656 | 1,340,119* | 964,676 | |
| Loss from operations | -2,341,383 | -2,191,656* | -1,903,743 | |
| Misc other income | - | 0* | 0 | |
| Reimbursement grant income | 102,425 | 234,051* | 183,281 | |
| Interest income | 47 | 842* | 572 | |
| Foreign exchange gain | -8,758 | 29,113* | -29,574 | |
| Nonoperating income (expense) | 93,714 | 264,006* | 154,279 | |
| Loss before income taxes | - | -1,927,650* | -1,749,464 | |
| Income tax expense | - | 800* | 0 | |
| Net loss | -2,247,669 | -1,928,450* | -1,749,464 | |
| Exchange differences on translation | -5,315 | -416,991* | 164,611 | |
| Net comprehensive loss | -2,252,984 | -2,345,441 | -1,584,853 | |
| Basic EPS | -0.28 | -0.542 | -0.25 | |
| Basic Average Shares | 7,972,532 | 4,330,738 | 7,022,678 | |
Edesa Biotech, Inc. (EDSA)
Edesa Biotech, Inc. (EDSA)